Low-temperature crystal structures of Tetrakis-μ-3,5- diisopropylsalicylatobis-dimethylformamidodicopper(II) and Tetrakis-μ-3,5- diisopropylsalicylatobis-diethyletheratodicopper(II) and their role in modulating polymorphonuclear leukocyte activity in overcoming seizures

Journal of Inorganic Biochemistry

Volumn 81, Issue 1-2, 2000, Pages 11-22

  Morgant, Georges ^a,c   Dung, Nguyen Huy ^a   Daran, Jean Claude ^b   Viossat, Bernard ^d   Labouze, Xavier ^a   Roch Arveiller, Monique ^e   Greenaway, Frederick T ^f   Cordes, Wally ^g   Sorenson, John R J ^h  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b LCC LABORATOIRE DE CHIMIE DE COORDINATION   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d Laboratoire de Chimie Generale   (France)

^e Hop Cochin ^*  (France)

^f CLARK UNIVERSITY   (United States)

^g UNIVERSITY OF ARKANSAS   (United States)

^h Dept Pharmaceutical Sci Coll P   (United States)

Author keywords

Anti inflammatory; Anticonvulsant; Crystallography; Ternary copper(II) complexes

Indexed keywords

3,5 DIISOPROPYLSALICYLATE COPPER; 3,5 DIISOPROPYLSALICYLIC ACID; COPPER COMPLEX; ETHER; N,N DIMETHYLFORMAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTETRAZOLE; SALICYLIC ACID DERIVATIVE; TETRAKIS MU 3,5 DIISOPROPYLSALICYLATOBIS DIETHYLETHERATODICOPPER; TETRAKIS MU 3,5 DIISOPROPYLSALICYLATOBIS DIMETHYLFORMAMIDODICOPPER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPLEX FORMATION; CRYSTAL STRUCTURE; EPILEPSY; LEUKOCYTE; MALE; NONHUMAN; RAT; SEIZURE; X RAY DIFFRACTION;

ANIMALIA;

EID: 0034661009     PISSN: 01620134     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-0134(00)00107-0     Document Type: Article

References (33)

1. Sorenson J.R.J. Prog. Med. Chem. 26:1989;437-568.
2. Sorenson J.R.J. Berthon G. Handbook of Metal-Ligand Interactions in Biological Fluids: Bioinorganic Medicine. Vol. 2:1995;1318-1324 Marcel Dekker, New York.
3. Sorenson J.R.J. Berthon G. Handbook of Metal-Ligand Interactions in Biological Fluids: Bioinorganic Medicine. Vol. 2:1995;1128-1139 Marcel Dekker, New York.
4. Baquial J.G.L., Sorenson J.R.J. J. Inorg. Biochem. 60:1995;133-148.
5. Booth B.L., Pitters E., Mayer B., Sorenson J.R.J. Metal-Based Drugs. 6:1999;111-120.
6. Mayer B., Pfeiffer S., Leopold E., Muller J., Weser U., Schmidt K. Neurosci. Lett. 209:1996;169-172.
7. Greenaway F.T., Norris L.J., Sorenson J.R.J. Inorg. Chim. Acta. 145:1998;279-284.
8. Sorenson J.R.J. J. Med. Chem. 19:1976;135-148.
9. Altomare A., Cascarano G., Giacovazzo G., Guagliardi A., Burla M.C., Polidori G., Camalli M. J. Appl. Cryst. 27:1994;435.
10. G.M. Sheldrick, SHELXL-97, Program for Crystal Structure Refinement, University of Gottingen, 1997.
11. Watkin D.J., Prout C.K., Pearce L.J. CAMERON, Chemical Crystallography Laboratory. 1996;University of Oxford, Oxford.
12. J.D. Ranford, P.J. Sadler, D.A. Tocher, J. Chem. Soc. Dalton Trans. (1993) 3393-3399.
13. Roch-Arveiller M., Relevant V., Pham Huy D., Marnan L., Fontagne J., Sorenson J.R.J., Giroud J.-P. Agents Actions. 31:1990;65-71.
14. C. Dendrinou-Samara, D.P. Kessioglou, G.E. Manoussakis, D. Mentzasos, A. Terzis, J. Chem. Soc. Dalton Trans. (1990) 959-965.
15. Kovala-Demertzi D., Theodorou A., Demertzis M.A., Raptopoulou C., Terzis A. J. Inorg. Biochem. 65:1997;151-157.
16. Guessous F., Daran J.-C., Viossat B., et al. Metal-Based Drugs. 5:1998;337-345.
17. Greenaway F.T., Riviere E., Gererd J.-J., et al. J. Inorg. Biochem. 76:1999;19-27.
18. Lee J.D. A New Concise Inorganic Chemistry. 3rd Edition :1986;Van Nostrand Reinhold, London.
19. Hökelek T., Necefgolu H., Balci M. Acta. Crystallog. C51:1995;2020-2023.
20. Kawata T., Uekasa H., Furikawa T., Tokii T., Muto Y. Acta. Cryst. B48:1992;253-261.
21. P. Meester, S.R. Fletcher, A.C. Skapski, J. Chem. Soc. Trans. (1973) 2575-2578.
22. Morgant G., Viossat B., Daran J.-C., Roch-Arveiller M., Giroud J.-P., Nguyer-Huy D., Sorenson J.R.J. J. Inorg. Biochem. 70:1998;137-143.
23. Gay J.C., Lukens J.N., English D.K. Inflammation. 8:1984;209-222.
24. Kaim W., Rall J. Angew. Chem. Int., Engl. Ed. 35:1996;43-60.
25. Yatsuyanagi J., Ogiso T. Chem. Pharm. Bull. 36:1988;1035-1040.
26. Forbes I.J., Zalewski P.D., Giannakis C. Exp. Cell. Res. 195:1991;224-229.
27. Nilsson K. Cancer Lett. 47:1989;169-177.
28. Singla A.K., Medittara D.K., Pathak K. Int. J. Pharmaceut. 60:1990;27-33.
29. Bonomo R.P., De Flora A., Rizzarelli E., Santoro A.M., Tabbi G., Tonetti M. J. Inorg. Biochem. 59:1995;773-784.
30. Sorenson J.R.J., Soderberg L.S.F., Chang L.W. Proced. Soc. Exptl. Biol. Med. 210:1995;191-204.
31. Chidambaram M.V., Epperson C.E., Williams S., Gray R.A., Sorenson J.R.J. J. Label. Cpds. Radiopharmaceu. XXIX:1991;273-288.
32. Sorenson J.R.J., Soderberg L.S.F., Baker M.L., Barnett J.B., Chang L.W., Salari H., Willingham W.M. Emerit I., Auclair C., Packer L. Advances in Experimental Medicine and Biology: Anitoxidants in Therapy and Preventative Medicine. Vol. 264:1990;69-78 Plenum Press, New York.
33. Albert A. Johnson L.A., Seven M.J. Federation. Proceedings, Suppl. 10, Part II, Federation of American Societies for Experimental Biology, Washington, D.C :1961;137-147.